# Possible Effects of New National Allocation Policy for Deceased Donor Kidneys in the US

Ajay Israni, M.D, M.S. Deputy Director, SRTR

Associate Professor of Medicine, Hennepin County Medical Center, Faculty, Epidemiology & Community Health, University of Minnesota

July 29, 2014





World Transplant Congress



Ajay Israni, M.D., M.S. Deputy Director, Scientific Registry of Transplant Recipients

Associate Professor of Medicine, Hennepin County Medical Center University of Minnesota

I have no financial relationships to disclose within the past 12 months relevant to my presentation. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

#### **AND**

My presentation does/does not include discussion of off-label or investigational use. I do/do not intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

This work was supported wholly or in part by HRSA contract 250201000018C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of HHS, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

### SRTR's complementary role to the OPTN

OPTN	SRTR
Organ Allocation / Policy Development	Research / Policy Evaluation

When a committee is considering a change to allocation policy, the committee members may wish to simulate what changes may occur if the policy is implemented. SRTR uses Simulated Allocation Modeling Software to accomplish this goal.

The new kidney allocation policy's effects on mortality among older candidates and access to transplant based on dialysis time are unknown.



### Overview of allocation components by run

Concepts	Current	New
SCD allocation (defined as KDPI ≤ .85 for new policy)	X	X
DCD allocation	X	
ECD allocation (defined as KDPI > .85 for new policy)	X	X
Payback system	X	
Waiting time since listing	X	
Back-dating dialysis time		X
Waiting time points based on fractional years		X
A2/A2B donor to B candidates priority(local, regional, and national)		X
Highest scoring high CPRA classification	X	
Pediatrics cannot receive non-0 mm ECD offers		X




### **Overview (continued)**

Concepts	Current	New
Longevity matching (top 20% survivors get first chance at top 20% kidneys)		X
"Share 0.35" pediatric priority in new policy (Donor < 35 yrs for Current)	X	X
CPRA sliding scale		X
National priority sharing for CPRA 100%, regional priority sharing for CPRA 99%, local priority for CPRA 98% candidates		X
Regional sharing for marginal kidneys (KDPI>.85)		Χ
KP/PA System: current	X	
KP/PA system: future		X



### Allocation modeling flow chart






### **Results of simulations**

Average for 10 iterations	Current	New
Number of candidates (on waitlist at start or joining during run)	122,669	122,669
Average number of primary transplant recipients (KI+KP)	11,531 (11,463-11,586)	11,599 (11,538-11,681)
Average median lifespan post-transplant (min, max of runs)	11.82 (11.75 - 11.85)	12.65 (12.61-12.71)
Average median graft years of life (min, max of runs)	8.82 (8.80-8.84)	9.07 (9.05-9.08)
Average median extra life-years for tx recipient versus waitlist candidate (min, max of runs)	5.01 (4.99-5.03)	5.24 (5.22-5.27)




## Percentage of deaths on the waiting list: actual 5,444 in 2010






### **Pre-emptive transplants by race**






### Number of years of dialysis at transplant





### Dialysis time prior to listing





### Summary of results for kidney allocation policy

- The new policy simulation showed :
  - No substantial increases in mortality on the waiting list
  - Pre-emptive transplants increase, for Caucasian & African-American
  - Dialysis time at transplant was re-distributed
    - More transplants for candidates with less than 3 years on dialysis
    - Fewer transplants for candidates with more then 3 years on dialysis
  - Dialysis time at time of listing did not change substantially



### **Future directions**

- Monitor for expected consequences
- Intended & unintended consequences




### **Limitations of current system**

- Variability in access to transplantation by candidate blood type
- High discard rates of kidneys
- Differences in access to transplantation for populations such as candidates with high CPRA
- Kidneys with long potential longevity allocated to candidates with significantly shorter longevity and vice versa
  - Results in unrealized graft years and high retransplant rates



### KDPI: correlated with graft survival





### **Estimated post-transplant survival (EPTS)**

- Based on following recipient factors:
  - Candidate age
  - Length of time on dialysis
  - Prior transplant (any organ)
  - Diabetes status

(All negative factors, leading to higher EPTS score)

Higher EPTS score = lower expected patient survival



New proposed national allocation policy: CPRA sliding scale

- Currently, candidates with a CPRA of 80% or greater get 4 points; candidates with a CPRA below 80 get no additional points.
- To mediate the "spike" in points at 80, the kidney committee, along with histocompatibility committee, developed the CPRA sliding scale.

CPRA	Points
0-19	0
20 - 29	0.08
30-39	0.21
40 - 49	0.34
50 - 59	0.48
60 - 69	0.81
70 - 74	1.09
75 - 79	1.58
80 - 84	2.46
85 - 89	4.05
90 - 94	6.71
95	10.82
96	12.17
97	17.3
98	24.4
99	50.09
100	202.1




# Proposed point system to rank-order within each category

- 1 point per year (awarded as 1/365 point per day) for qualified time spent waiting
- 0-202 points based on degree of sensitization (CPRA)
- 4 points for prior living organ donors
- 1 point for pediatric candidates if donor is <35 yrs old</li>
- 4 points for pediatric candidates (age 0-10 at time of match)
   when offered a zero antigen mismatch
- 3 points for pediatric candidates (age 11-17 at time of match)
   when offered a zero antigen mismatch



## Percent of candidates in national top 20%, by Donor Service Area of candidate's listing center





## Percent of kidney donors in national top 20% (KDPI<0.20), by DSA of donor





### **Overview of N4**

<b>KDPI</b> ≤0.20	KDPI 0.21-0.34	KDPI 0.35-0.85	KDPI >0.85
Local CPRA 98+ Reg'l CPRA 99+ Nat' CPRA 100 Omm top 20 Local pediatrics Local top 20 Omm bottom 80 Local bottom 80 Reg'l pediatrics Reg'l top 20	Local CPRA 98+ Reg'l CPRA 99+ Nat'l CPRA 100 Omm Local pediatrics Local adults Reg'l pediatrics Reg'l adults Nat'l pediatrics Nat'l adults	Local CPRA 98+ Reg'l CPRA 99+ Nat'l CPRA 100 Omm Local Reg'l Nat'l	Local CPRA 98+ Reg'l CPRA 99+ Nat'l CPRA 100 Omm Local and reg'l adults Nat'l adults
Reg'l bottom 80 Nat'l pediatrics Nat'l top 20 Nat'l bottom 80	Trac radares	Тор	20 to Top 20



#### New policy and prioritizing sensitized candidates

#### N4

- Local CPRA 100
- Regional CPRA 100
- National CPRA 100
- Local CPRA 99
- Regional CPRA 99
- Local CPRA 98

first priority for all kidneys





### Average primary KI + KP transplants per run







### Kidney transplants by recipient blood type





### Kidney transplants by recipient age






### Counts of kidney transplants, by recipient age


		Age Group								
Run	<18	vs N1	18-34	vs N1	35-49	vs N1	50-64	vs N1	65+	vs N1
N1	529		1120	-	2719	-	4437	-	1991	-
N4	487	-42	1692	+572	3015	+296	4054	-383	1723	-268



# Kidney transplants by recipient CPRA, with waitlist prevalence




### Kidney transplants by recipient cPRA=0






### Kidney transplants by recipient cPRA, 1-69





### Kidney transplants by recipient cPRA, 70-94





### Kidney transplants by recipient cPRA, 95-100





# Kidney donor profile index (KDPI): A continuous scale, correlated with graft survival

- Donor factors used to calculate KDPI:
  - Age
  - Height
  - Weight
  - Ethnicity
  - History of hypertension
  - History of diabetes
  - Cause of death
  - Serum creatinine
  - Hepatitis C virus (HCV) status
  - Donation after circulatory death (DCD) status



### **Acknowledgments**

- Jon Snyder, PhD
- Bertram Kasiske, MD
- Allyson Hart, MD, MS
- Sally Gustafson, MS
- Nicholas Salkowski, PhD

